Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Status:
Withdrawn
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular
degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV)
due to other causes. The limitation of this type of treatment is the necessity for frequent
intraocular injections. The purpose of this study is to determine if using anti-VEGF therapy
in combination with photodynamic therapy can reduce the number of treatments needed with
monotherapy while achieving similar visual results. There are ongoing multicenter trials
evaluating combination therapy in patients with wet AMD but no similar trial for patients
with CNV due to non-AMD causes. Therefore, in this study the investigators will focus on
patients with CNV not due to AMD.